Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsDominik Heger - Head of Investor RelationsHassan Al-Wakeel - DirectorHelen Giza - CEO and Chair of the Management BoardMartin Fischer - CFOConference Call ParticipantsGraham Doyle - Executive Director and Equity Research AnalystHugo Solvet - Research AnalystVeronica Clark - AnalystNone - AnalystNone - AnalystOperatorLadies and gentlemen, welcome to the report on the fourth quarter and financial year 202 ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsDominik Heger - Head of Investor RelationsHassan Al-Wakeel - DirectorHelen Giza - CEO and Chair of the Management BoardMartin Fischer - CFOConference Call ParticipantsGraham Doyle - Executive Director and Equity Research AnalystHugo Solvet - Research AnalystVeronica Clark - AnalystNone - AnalystNone - AnalystOperatorLadies and gentlemen, welcome to the Report on the Fourth Quarter and Financial Year 202 ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker3Ladies and gentlemen, welcome to the report on the fourth quarter and financial year 2025 conference call. I'm Moritz, the conference call operator. I would like to remind you that all participants will be in a listen-only mode, and the conference is being recorded. The presentation will be followed by a question-and-answer session. You can register for questions at any time by pressing star and one on your telepho ...

Helen Giza CEO & Chair of the Management Board Martin Fischer CFO February 24, 2026 Q4/FY 2025 Earnings Call Safe harbor statement: In this Safe harbor statement, "the Company" and "Fresenius Medical Care" refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conversion of legal form. This presentation includes certain forward-looking statements within the meaning o ...

December 31, 2025, 14.1 million shares were repurchased for a total investment amount of EUR 586 million. The second tranche of around EUR 414 million started on January 12, 2026, and is planned to end by May 8, 2026. The entire program is therefore expected to be completed in less than one year instead of within two years.In parallel, net financial debt was further reduced by 6% to EUR 9.2 billion. The corresponding net leverage ratio (net debt/EBITDA) decreased to 2.5x at the end of 2025, compared to 2.9x ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Company ParticipantsCarla Burigatto - EVP of Communications and Corporate AffairsHelen Giza - CEOMaria Rugamer - JournalistMartin Fischer - CFOPatricia Weiss - Senior CorrespondentNone - Company RepresentativeCarla BurigattoGood morning, and welcome to Fresenius Medical Care AG's annual press conference. My name is Carla Burigato, Executive Vice President, Communications and Corporate Affairs. I'm delighted to welcome you ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Company ParticipantsBritta Becks - Reporter and CorrespondentCarla Burigatto - EVP of Communications and Corporate AffairsHelen Giza - CEOMarcel Jan Dinkel - News ReporterMaria Rugamer - JournalistMartin Fischer - CFOPatricia Weiss - Senior CorrespondentSonja Wind - News ReporterCarla BurigattoGood morning, and welcome to Fresenius Medical Care AG's Annual Press Conference. My name is Carla Burigatto, Executive Vice Presid ...

Fresenius Medical Care (NYSE:FMS) Q4 2025 Earnings call February 24, 2026 04:00 AM ET Speaker0Good morning, and welcome to Fresenius Medical Care AG's annual press conference. My name is Carla Burigato, Executive Vice President, Communications and Corporate Affairs. I'm delighted to welcome you today and appreciate all the journalists joining via live stream. Today's press conference is virtual and being streamed publicly as a webcast in both English and German. You can select your preferred language at the ...

Fresenius Medical Care AG Investor Presentation FY 2025 Safe harbor statement: In this Safe harbor statement, "the Company" and "Fresenius Medical Care" refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conversion of legal form. This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as ...

Core Insights - Fresenius Medical Care has appointed Joseph E. Turk as the new Chief Executive Officer of the global operating segment Care Enablement, effective January 1, 2026, succeeding Dr. Katarzyna Mazur-Hofsäß who is retiring [1][2][7] Company Leadership Transition - The transition is part of a planned succession as Dr. Mazur-Hofsäß has informed the Supervisory Board of her intention to retire after leading Care Enablement since its inception in 2022 [2][4] - Joseph Turk has been with Fresenius Medical Care since 2019 and has held significant roles, including Executive Vice President of Global Home and Critical Care Therapies [3][4] Management Board Comments - Michael Sen, Chairman of the Supervisory Board, expressed confidence in Turk's ability to continue improving margins and advancing innovation within Care Enablement [4] - Helen Giza, CEO and Chair of the Management Board, highlighted Turk's strong track record and his role in executing the FME Reignite strategy [4] Company Overview - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally who undergo dialysis treatment [4] - The company operates a network of 3,676 dialysis clinics, providing treatments for around 300,000 patients worldwide [4]